NMDA NR1Alternative Names: NMDA-NR1
Latest Information Update: 07 Jul 2016
At a glance
- Originator JN-International Medical Corporation
- Class Neuroprotectants; Vaccines
- Mechanism of Action NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 07 Jul 2016 Preclinical trials in Stroke in USA (PO)